CancerVax was incorporated, raised $2 million seed funding and executed a Sponsored Research Agreement with UCLA targeting Ewing sarcoma.
CancerVax filed a provisional patent describing technology that forms the basis of our Universal Cancer Treatment Platform.
CancerVax executed a second Sponsored Research Agreement with UCLA to develop the Universal Cancer Treatment Platform.
CancerVax filed a provisional patent application describing a novel messenger RNA (mRNA) approach to DETECT and MARK cancer cells with precision.
CancerVax entered into a research agreement with Flashpoint Therapeutics to perform research on its newly patent-pending Universal Cancer Treatment platform.
Principal Scientist
Chief Scientific Advisor
Scientific Advisor
Scientific Advisor
Scientific Advisor
Years of collective
experience